Monograph Capital Partners — Full Portfolio

Maxion Therapeutics develops protein and antibody therapeutics using its patented KnotBody technology, which fuses cysteine-rich miniproteins (Knottins) into antibody binding loops to target ion channels and GPCRs.

BiotechHealthtechCambridge, GB

JMJohn McCafferty(Co-founder and CTO)inAneesh Karatt-Vellatt(Co-founder and CSO)in

Co-investorsLILifeArc VenturesGEGeneral CatalystSOSolasta Ventures

Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves.

BiotechHealthtechMedical DevicesWatertown, US

MATTHEW FRANKEL(Executive Officer)inPCPETER COUROSSI(Executive Officer)RICHARD BATYCKY(Executive Officer, Director)JAMES ELLIS(Executive Officer)MLMICHAEL LIPP(Executive Officer)inCSCHRISTOPHER SILBER(Executive Officer)in

Board seatFDFreddie Dear· per SEC Form D

Co-investorsCACanaan PartnersF-F-Prime CapitalMIMission BiocapitalOUOUP (Osage University Partners)OSOsage University Partners

Ascend is a gene-to-GMP development partner that helps life-science companies advance advanced therapy products from the research bench through clinical stages.

BiotechHealthtechMedical DevicesMunich, DE

Evis Hursever(Executive Officer)Wesley McConnell(Executive Officer)Michael Stella(Executive Officer, Director)William Hawkins(Executive Officer)

BoardMichael Beecham(Director)Andrew Kozlov(Director)

Co-investorsCACathay HealthDCDCVC (Data Collective)DIDigitalis Ventures

Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.

BiotechDeep TechMedical DevicesSan Diego, US

KFKevin Finney(Chairman, President and CEO)inJBJohn Borkholder(Executive Officer)in

BoardKBKristina Burow(Director)inTCThomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)

Co-investorsARARCH Venture PartnersCACanaan PartnersPFPfizer Venture InvestmentsSASamsara BioCapitalNENewpath Partners

AviadoBio is a gene therapy company developing adeno-associated viral (AAV) treatments for neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

BiotechDeep TechDigital HealthHealthtech

CSChris Shaw(Co-Founder & Chief Scientific and Clinical Advisor)inDYDo Young Lee(Co-Founder)YBYoun Bok Lee(Co-Founder)inLDLisa Deschamps(Chief Executive Officer)inGFGraeme Fielder(Chief Operating Officer)inABAlex Bloom(Chief Development Officer)in

Co-investorsADAdvent Life SciencesDEDementia DiscoveryF-F-Prime CapitalLILifeArc VenturesNENew Enterprise Associates (NEA)

Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.

BiotechDigital HealthHealthtechMedical DevicesFoster City, US

LLLou Lange(Founder)MLMichael L. Riordan(Founder)inDODaniel O'Dayin

Co-investorsAIAisling CapitalASAsset Management CompanyFRFrazier Life SciencesKLKleiner PerkinsLOLongitude CapitalLULumira Ventures+5 more

Biotech company developing antibodies to treat autoimmune and inflammatory diseases.

Co-investorsARArkin CapitalJEJeito CapitalALAlpha Wave GlobalARARCH Venture PartnersVIViking Global Investors

ODAIA offers Marketing Intelligence, a platform for pharmaceutical marketing and sales teams that ties channel-level actions to prescription (Rx) outcomes and coordinates healthcare provider (HCP) engagement across digital and field channels.

AI & Machine LearningDigital HealthHealthtechMarketing TechSaaSSales Tech

PPPhilip Poulidis(Founder)in

Co-investorsGRGraphite VenturesPAPanache VenturesSTStand Up VenturesTHThreshold VenturesTOToronto Innovation Acceleration PartnersWIWittington Ventures+5 more

Ollin Biosciences is a clinical-stage biopharmaceutical company that acquires and develops therapies for vision-threatening eye diseases, including wet age-related macular degeneration, diabetic macular edema, and thyroid eye disease.

BiotechMedical Devices

Co-investorsANAndreessen HorowitzTCTCG Crossover

Ouro Medicines is a biotechnology company developing cell-depleting therapies aimed at resetting the immune system to treat chronic immune-mediated diseases such as autoimmune and autoinflammatory conditions.

BiotechHealthtechSouth San Francisco, US

Jaideep(Founding Chief Executive Officer)NMNeely Mozaffarian(Chief Medical Officer)inCChristina(General Counsel & Chief Operating Officer)

Co-investorsNENew Enterprise Associates (NEA)NONorwest Venture PartnersTPTPG

Prolynx develops ultra-long-acting therapeutics for obesity and metabolic diseases such as type 2 diabetes, using a hydrogel-based microsphere platform with tunable release linker chemistry to control drug release over extended dosing intervals.

BiotechDeep Tech

GAGary Ashley(Co-Founder)inDSDaniel Santi(Co-Founder)inCBChris Boulton(CEO)inSimon Harnest(Chief Financial Officer)inAMAmer Mirza(Chief Scientific Officer)inCWChristian Weyer(Chief Medical Officer)in

Co-investorsOROrbiMed

RegASK provides an AI-native regulatory intelligence platform that monitors regulatory changes across 160+ markets, orchestrates compliance workflows, and pairs automation with a community of regulatory experts for validation.

AI & Machine LearningEnterprise SoftwareSaaS

CSCaroline Shleifer(Founder)in

Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions.

BiotechHealthtechMedical DevicesMenlo Park, US

Jim Bristol(Director)DEDaniel Estes(Director)inSBScott Byrd(Executive Officer, Director)in

Co-investorsFRFrazier Life SciencesSASanofi VenturesSVSV Health InvestorsDEDementia Discovery FundFRFrazier Healthcare PartnersTPTPG

UroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology.

BiotechHealthtechMedical DevicesPrinceton, US

Mark Schoenberg, M.D.(Executive Officer)LBLiz Barrett(President and Chief Executive Officer)inJason Smith(Executive Officer)Arie Belldegrun, M.D.(Director)Dan Wildman(Director)Don Kim(Executive Officer)

Co-investorsAIAisling CapitalPOPontifax Venture Capital